Abstract
No public abstract is available from the verified source records.
Anna Metodieva, Jana Karbanová, Claudia Chiriches, Afsar Ali Mian, Peter Carmeliet, Marc Tjwa, Denis Corbeil, Martin Ruthardt
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
10.1016/j.blre.2021.100825 · 2021
The biology of chronic myeloid leukemia
10.1056/nejm199907153410306 · 1999
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation
10.1038/leu.2014.326 · 2015
Reversibility of acute B-cell leukaemia induced by BCR-ABL1
10.1038/71691 · 2000
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
10.1084/jem.189.9.1399 · 1999
Targeting BCR-ABL1-positive leukaemias: a review article
10.1017/pcm.2023.9 · 2023
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
10.1038/nature21702 · 2017
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
10.1172/jci30890 · 2007
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
10.1038/leu.2010.238 · 2011
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
Philadelphia chromosome-positive cells are equally distributed in AC133+ and AC133- fractions of CD34+ peripheral blood progenitor cells from patients with CML
10.1038/sj.leu.2401516 · 1999
Characterization of prominin-2, a new member of the prominin family of pentaspan membrane glycoproteins
10.1074/jbc.m210640200 · 2003
Nomenclature of prominin-1 (CD133) splice variants - an update
10.1111/j.1399-0039.2007.00825.x · 2007
AC133, a novel marker for human hematopoietic stem and progenitor cells
10.1182/blood.v90.12.5002 · 1997
A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning
10.1182/blood.v90.12.5013 · 1997
Emerging roles of prominin-1 (CD133) in the dynamics of plasma membrane architecture and cell signaling pathways in health and disease
10.1186/s11658-024-00554-0 · 2024
Isolation and characterization of human CD34(-)Lin(-) and CD34(+)Lin(-) hematopoietic stem cells using cell surface markers AC133 and CD7
10.1182/blood.v95.9.2813.009k20_2813_2820 · 2000
Comparative analysis of proliferative potential and clonogenicity of MACS-immunomagnetic isolated CD34+ and CD133+ blood stem cells derived from a single donor
10.1111/j.1365-2184.2006.00386.x · 2006
Multipotent hematopoietic progenitors divide asymmetrically to create progenitors of the lymphomyeloid and erythromyeloid lineages
10.1016/j.stemcr.2014.09.016 · 2015
CD133 is a modifier of hematopoietic progenitor frequencies but is dispensable for the maintenance of mouse hematopoietic stem cells
10.1073/pnas.1215438110 · 2013
The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions
10.1074/jbc.275.8.5512 · 2000
Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration
10.1523/jneurosci.2034-08.2009 · 2009
Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells
10.1073/pnas.94.23.12425 · 1997
Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane
10.1038/35023524 · 2000
Haematopoietic stem cell differentiation promotes the release of prominin-1/CD133-containing membrane vesicles–a role of the endocytic-exocytic pathway
10.1002/emmm.201100147 · 2011
Prominin-1 controls stem cell activation by orchestrating ciliary dynamics
10.15252/embj.201899845 · 2019
Prominin-1 (CD133) modulates the architecture and dynamics of microvilli
10.1111/tra.12618 · 2019
Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells
10.1242/jcs.02439 · 2005
The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases
10.1021/bi900159d · 2009
Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells
10.1073/pnas.1217002110 · 2013
CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges
2013
Targeting CD133 antigen in cancer
10.1517/14728220903005616 · 2009
AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors
10.1182/blood.v94.2.832 · 1999
Expression of AC133 and CD117 on candidate normal stem cell populations in childhood B-cell precursor acute lymphoblastic leukaemia
10.1046/j.1365-2141.1999.01746.x · 1999
p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia
10.3324/haematol.2011.047191 · 2012
BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity
2000
Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571
10.1182/blood-2003-03-0811 · 2003
on behalf of the GMALL study group. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia
10.1038/leu.2012.352 · 2013
Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL
10.1002/ijc.23467 · 2008
The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia
10.1369/jhc.2008.951897 · 2008
The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation
10.1038/leu.2010.180 · 2010
Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia
10.1016/j.bbapap.2005.07.040 · doi-reference
A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl
10.1021/jm901808w · doi-reference
A general strategy for creating "inactive-conformation" abl inhibitors
10.1016/j.chembiol.2006.05.015 · doi-reference
Allosteric kinase inhibition in hematological malignancies: from asciminib to emerging regulatory sites
10.1016/j.bcp.2026.118436 · doi-reference
Kinase-targeted cancer therapies: progress, challenges and future directions
10.1186/s12943-018-0804-2 · doi-reference
Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice
10.1634/stemcells.2005-0290 · doi-reference
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
10.1182/blood-2001-12-0181 · doi-reference
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
10.1056/nejm200104053441401 · doi-reference
CD133 in Breast Cancer Cells: More than a Stem Cell Marker
10.1155/2019/7512632 · doi-reference
5-Lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia
10.1158/0008-5472.can-13-3012 · doi-reference
Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors
10.1016/j.exphem.2008.11.002 · doi-reference
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia
10.1371/journal.pone.0080070 · doi-reference
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
10.1182/blood-2002-09-2780 · doi-reference